Adenosine signalling in diabetes mellitus-pathophysiology and therapeutic considerations

Nature Reviews Endocrinology

Volumn 11, Issue 4, 2015, Pages 228-241

  Antonioli, Luca ^a   Blandizzi, Corrado ^a   Csóka, Balázs ^b   Pacher, Pál ^c   Haskó, György ^b  

^a UNIVERSITY OF PISA   (Italy)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^c NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; GLUCOSE; INSULIN; ADENOSINE RECEPTOR;

ADIPOSE TISSUE; CARDIOVASCULAR DISEASE; DENDRITIC CELL; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; GLUCOSE HOMEOSTASIS; HOMEOSTASIS; HUMAN; IMMUNOCOMPETENT CELL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; LYMPHOCYTE; MICROENVIRONMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; DIABETES MELLITUS; METABOLISM;

ADENOSINE; ANIMALS; DIABETES MELLITUS; HUMANS; INSULIN RESISTANCE; RECEPTORS, PURINERGIC P1; SIGNAL TRANSDUCTION;

EID: 84925849428     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2015.10     Document Type: Review

References (168)

1. Shaw, J. E., Sicree, R. A. & Zimmet, P. Z. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res. Clin. Pract. 87, 4-14 (2010).
2. Centers for Disease Control and Prevention. National diabetes statistics report, 2014 [online], http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf (2014).
3. st century challenge. Lancet Diabetes Endocrinol. 2, 56-64 (2014).
4. Canivell, S. & Gomis, R. Diagnosis and classification of autoimmune diabetes mellitus. Autoimmun. Rev. 13, 403-407 (2014).
5. Tuomi, T. et al. The many faces of diabetes: a disease with increasing heterogeneity. Lancet 383, 1084-1094 (2014).
6. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 37 (Suppl. 1), S81-S90 (2014).
7. Antonioli, L., Blandizzi, C., Pacher, P. & Hasko, G. Immunity, inflammation and cancer: a leading role for adenosine. Nat. Rev. Cancer 13, 842-857 (2013).
8. Koupenova, M. & Ravid, K. Adenosine, adenosine receptors and their role in glucose homeostasis and lipid metabolism. J. Cell. Physiol. http://dx.doi.org/10.1002/jcp.24352.
9. Grden, M., Podgorska, M., Szutowicz, A. & Pawelczyk, T. Diabetes-induced alterations of adenosine receptors expression level in rat liver. Exp. Mol. Pathol. 83, 392-398 (2007).
10. Eisenstein, A. & Ravid, K. G protein-coupled receptors and adipogenesis: a focus on adenosine receptors. J. Cell. Physiol. 229, 414-421 (2014).
11. Hasko, G., Linden, J., Cronstein, B. & Pacher, P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat. Rev. Drug Discov. 7, 759-770 (2008).
12. 1 receptor expression in pancreatic α-cells may contribute to the pathology of type 1 diabetes. Diabetes 62, 4208-4219 (2013).
13. 2B adenosine receptors prevent insulin resistance by inhibiting adipose tissue inflammation via maintaining alternative macrophage activation. Diabetes 63, 850-866 (2014).
14. 2b adenosine receptor modulates glucose homeostasis and obesity. PLoS ONE 7, e40584 (2012).
15. 3 receptors in modulation of insulin secretion and β-cell survival in mouse pancreatic islets. Gen. Comp. Endocrinol. 187, 86-94 (2013).
16. 1 receptor knockout mice. Am. J. Physiol. Endocrinol. Metab. 303, E180-E190 (2012).
17. 1 receptor deficiency causes increased insulin and glucagon secretion in mice. Biochem. Pharmacol. 74, 1628-1635 (2007).
18. Andersson, O. Role of adenosine signalling and metabolism in β-cell regeneration. Exp. Cell Res. 321, 3-10 (2014).
19. 1 receptor signaling. Diabetes 60, 2578-2587 (2011).
20. 2B receptors, and inflammatory markers in mice and humans. Diabetes 60, 669-679 (2011).
21. Antonioli, L. et al. The role of purinergic pathways in the pathophysiology of gut diseases: pharmacological modulation and potential therapeutic applications. Pharmacol. Ther. 139, 157-188 (2013).
22. Antonioli, L. et al. Regulation of enteric functions by adenosine: pathophysiological and pharmacological implications. Pharmacol. Ther. 120, 233-253 (2008).
23. Antonioli, L., Pacher, P., Vizi, E. S. & Hasko, G. CD39 and CD73 in immunity and inflammation. Trends Mol. Med. 19, 355-367 (2013).
24. Antonioli, L. et al. Adenosine deaminase in the modulation of immune system and its potential as a novel target for treatment of inflammatory disorders. Curr. Drug Targets 13, 842-862 (2012).
25. Boison, D. Adenosine kinase: exploitation for therapeutic gain. Pharmacol. Rev. 65, 906-943 (2013).
26. Hardie, D. G. AMPK: a key regulator of energy balance in the single cell and the whole organism. Int. J. Obes. (Lond.) 32 (Suppl. 4), S7-S12 (2008).
27. Brezar, V., Carel, J. C., Boitard, C. & Mallone, R. Beyond the hormone: insulin as an autoimmune target in type 1 diabetes. Endocr. Rev. 32, 623-669 (2011).
28. Wallberg, M. & Cooke, A. Immune mechanisms in type 1 diabetes. Trends Immunol. 34, 583-591 (2013).
29. Chia, J. S., McRae, J. L., Cowan, P. J. & Dwyer, K. M. The CD39-adenosinergic axis in the pathogenesis of immune and nonimmune diabetes. J. Biomed. Biotechnol. 2012, 320495 (2012).
30. Peiris, H., Bonder, C. S., Coates, P. T., Keating, D. J. & Jessup, C. F. The β-cell/EC axis: how do islet cells talk to each other? Diabetes 63, 3-11 (2014).
31. Wang, Z. & Thurmond, D. C. Mechanisms of biphasic insulin-granule exocytosis-roles of the cytoskeleton, small GTPases and SNARE proteins. J. Cell Sci. 122, 893-903 (2009).
32. Novak, I. Purinergic receptors in the endocrine and exocrine pancreas. Purinergic Signal. 4, 237-253 (2008).
33. Nemeth, Z. H. et al. Adenosine receptor activation ameliorates type 1 diabetes. FASEB J. 21, 2379-2388 (2007).
34. 2+ uptake. Cell Biochem. Funct. 26, 833-843 (2008).
35. 1 subtype adenosine receptor on pancreatic insulin-secreting cells. Eur. J. Pharmacol. 136, 109-112 (1987).
36. Bertrand, G., Petit, P., Bozem, M. & Henquin, J. C. Membrane and intracellular effects of adenosine in mouse pancreatic β-cells. Am. J. Physiol. 257, E473-E478 (1989).
37. Verspohl, E. J., Johannwille, B., Waheed, A. & Neye, H. Effect of purinergic agonists and antagonists on insulin secretion from INS-1 cells (insulinoma cell line) and rat pancreatic islets. Can. J. Physiol. Pharmacol. 80, 562-568 (2002).
38. 2B receptors on glucose homeostasis. J. Pharm. Pharmacol. 58, 1639-1645 (2006).
39. Annes, J. P. et al. Adenosine kinase inhibition selectively promotes rodent and porcine islet β-cell replication. Proc. Natl Acad. Sci. USA 109, 3915-3920 (2012).
40. Andersson, O. et al. Adenosine signaling promotes regeneration of pancreatic β cells in vivo. Cell Metab. 15, 885-894 (2012).
41. Lehuen, A., Diana, J., Zaccone, P. & Cooke, A. Immune cell crosstalk in type 1 diabetes. Nat. Rev. Immunol. 10, 501-513 (2010).
42. Ghaemi Oskouie, F. et al. High levels of adenosine deaminase on dendritic cells promote autoreactive T cell activation and diabetes in nonobese diabetic mice. J. Immunol. 186, 6798-6806 (2011).
43. Sakowicz-Burkiewicz, M. & Pawelczyk, T. Recent advances in understanding the relationship between adenosine metabolism and the function of T and B lymphocytes in diabetes. J. Physiol. Pharmacol. 62, 505-512 (2011).
44. Novitskiy, S. V. et al. Adenosine receptors in regulation of dendritic cell differentiation and function. Blood 112, 1822-1831 (2008).
45. Kumar, V. Adenosine as an endogenous immunoregulator in cancer pathogenesis: where to go? Purinergic Signal. 9, 145-165 (2013).
46. Linden, J. & Cekic, C. Regulation of lymphocyte function by adenosine. Arterioscler. Thromb. Vasc. Biol. 32, 2097-2103 (2012).
47. 2A adenosine receptors in the T cell-mediated regulation of colitis. J. Immunol. 177, 2765-2769 (2006).
48. Sevigny, C. P. et al. Activation of adenosine 2A receptors attenuates allograft rejection and alloantigen recognition. J. Immunol. 178, 4240-4249 (2007).
49. + T cells. J. Immunol. 174, 1073-1080 (2005).
50. 2A receptor activation inhibits T helper 1 and T helper 2 cell development and effector function. FASEB J. 22, 3491-3499 (2008).
51. Linnemann, C. et al. Adenosine regulates CD8 T-cell priming by inhibition of membrane-proximal T-cell receptor signalling. Immunology 128, e728-e737 (2009).
52. 2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion. Blood 90, 1600-1610 (1997).
53. 2A purinergic receptor-mediated signaling in murine T cells. J. Biol. Chem. 272, 25881-25889 (1997).
54. Tai, N., Wong, F. S. & Wen, L. TLR9 deficiency promotes CD73 expression in T cells and diabetes protection in nonobese diabetic mice. J. Immunol. 191, 2926-2937 (2013).
55. Chia, J. S. et al. The protective effects of CD39 overexpression in multiple low-dose streptozotocin-induced diabetes in mice. Diabetes 62, 2026-2035 (2013).
56. Morel, P. A. Dendritic cell subsets in type 1 diabetes: friend or foe? Front. Immunol. 4, 415 (2013).
57. 2B adenosine receptor impairs the maturation and immunogenicity of dendritic cells. J. Immunol. 182, 4616-4623 (2009).
58. Desrosiers, M. D. et al. Adenosine deamination sustains dendritic cell activation in inflammation. J. Immunol. 179, 1884-1892 (2007).
59. + T cells in type 1 diabetes. Adv. Immunol. 100, 79-124 (2008).
60. McCarthy, M. I. Genomics, type 2 diabetes, and obesity. N. Engl. J. Med. 363, 2339-2350 (2010).
61. Esser, N., Legrand-Poels, S., Piette, J., Scheen, A. J. & Paquot, N. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res. Clin. Pract. 105, 141-150 (2014).
62. Guilherme, A., Virbasius, J. V., Puri, V. & Czech, M. P. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat. Rev. Mol. Cell Biol. 9, 367-377 (2008).
63. Karsak, M. et al. Attenuation of allergic contact dermatitis through the endocannabinoid system. Science 316, 1494-1497 (2007).
64. Capogrossi, M. C. et al. Adenosine release from isolated rat adipocytes: influence of fat cell concentration and cell size. Proc. Soc. Exp. Biol. Med. 182, 15-22 (1986).
65. Schwabe, U., Ebert, R. & Erbler, H. C. Adenosine release from fat cells: effect on cyclic AMP levels and hormone actions. Adv. Cyclic Nucleotide Res. 5, 569-584 (1975).
66. 2b adenosine receptors on adipogenesis. Int. J. Obes. (Lond.) 36, 397-406 (2012).
67. 1H-spectroscopy, and glucose clamp studies. Diabetes 53, 1920-1926 (2004).
68. 1 adenosine receptor agonist devoid of cardiovascular effects: comparison with nicotinic acid. J. Pharmacol. Exp. Ther. 321, 327-333 (2007).
69. 1 adenosine receptor partial agonist lowers plasma FFA and improves insulin resistance induced by high-fat diet in rodents. Am. J. Physiol. Endocrinol. Metab. 292, E1358-E1363 (2007).
70. 2A receptors. Nature 516, 395-399 (2014).
71. 2b adenosine receptor regulates tissue insulin sensitivity. PLoS ONE 9, e98775 (2014).
72. 2B receptors. FASEB J. 26, 376-386 (2012).
73. Chawla, A., Nguyen, K. D. & Goh, Y. P. Macrophage-mediated inflammation in metabolic disease. Nat. Rev. Immunol. 11, 738-749 (2011).
74. Thong, F. S. & Graham, T. E. The putative roles of adenosine in insulin-and exercise-mediated regulation of glucose transport and glycogen metabolism in skeletal muscle. Can. J. Appl. Physiol. 27, 152-178 (2002).
75. Leighton, B. et al. Effects of adenosine deaminase on the sensitivity of glucose transport, glycolysis and glycogen synthesis to insulin in muscles of the rat. Int. J. Biochem. 20, 23-27 (1988).
76. Stace, P. B., Marchington, D. R., Kerbey, A. L. & Randle, P. J. Long term culture of rat soleus muscle in vitro. Its effects on glucose utilization and insulin sensitivity. FEBS Lett. 273, 91-94 (1990).
77. 1 adenosine receptor increases insulin-stimulated glucose transport in isolated rat soleus muscle. Appl. Physiol. Nutr. Metab. 32, 701-710 (2007).
78. Vergauwen, L., Hespel, P. & Richter, E. A. Adenosine receptors mediate synergistic stimulation of glucose uptake and transport by insulin and by contractions in rat skeletal muscle. J. Clin. Invest. 93, 974-981 (1994).
79. Han, D. H., Hansen, P. A., Nolte, L. A. & Holloszy, J. O. Removal of adenosine decreases the responsiveness of muscle glucose transport to insulin and contractions. Diabetes 47, 1671-1675 (1998).
80. Challiss, R. A., Richards, S. J. & Budohoski, L. Characterization of the adenosine receptor modulating insulin action in rat skeletal muscle. Eur. J. Pharmacol. 226, 121-128 (1992).
81. Turcotte, L. P. & Fisher, J. S. Skeletal muscle insulin resistance: roles of fatty acid metabolism and exercise. Phys. Ther. 88, 1279-1296 (2008).
82. Nuttall, F. Q., Ngo, A. & Gannon, M. C. Regulation of hepatic glucose production and the role of gluconeogenesis in humans: is the rate of gluconeogenesis constant? Diabetes Metab. Res. Rev. 24, 438-458 (2008).
83. Wilcox, G. Insulin and insulin resistance. Clin. Biochem. Rev. 26, 19-39 (2005).
84. Lewis, G. F., Carpentier, A., Adeli, K. & Giacca, A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr. Rev. 23, 201-229 (2002).
85. McLane, M. P., Black, P. R., Law, W. R. & Raymond, R. M. Adenosine reversal of in vivo hepatic responsiveness to insulin. Diabetes 39, 62-69 (1990).
86. Hoffer, L. J. & Lowenstein, J. M. Effects of adenosine and adenosine analogues on glycogen metabolism in isolated rat hepatocytes. Biochem. Pharmacol. 35, 4529-4536 (1986).
87. 2+ and cAMP. Eur. J. Pharmacol. 437, 105-111 (2002).
88. Yasuda, N. et al. Functional characterization of the adenosine receptor contributing to glycogenolysis and gluconeogenesis in rat hepatocytes. Eur. J. Pharmacol. 459, 159-166 (2003).
89. 2B receptor. J. Med. Chem. 44, 170-179 (2001).
90. Krauss, R. M. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care 27, 1496-1504 (2004).
91. Yu, Y. H. & Ginsberg, H. N. Adipocyte signaling and lipid homeostasis: sequelae of insulin-resistant adipose tissue. Circ. Res. 96, 1042-1052 (2005).
92. Xu, X., So, J. S., Park, J. G. & Lee, A. H. Transcriptional control of hepatic lipid metabolism by SREBP and ChREBP. Semin. Liver Dis. 33, 301-311 (2013).
93. Halperin, I. J. & Feig, D. S. The role of lifestyle interventions in the prevention of gestational diabetes. Curr. Diab. Rep. 14, 452 (2014).
94. Pardo, F. et al. Role of equilibrative adenosine transporters and adenosine receptors as modulators of the human placental endothelium in gestational diabetes mellitus. Placenta 34, 1121-1127 (2013).
95. San Martin, R. & Sobrevia, L. Gestational diabetes and the adenosine/l-arginine/nitric oxide (ALANO) pathway in human umbilical vein endothelium. Placenta 27, 1-10 (2006).
96. Vasquez, G. et al. Role of adenosine transport in gestational diabetes-induced l-arginine transport and nitric oxide synthesis in human umbilical vein endothelium. J. Physiol. 560, 111-122 (2004).
97. Aguayo, C. et al. Equilibrative nucleoside transporter 2 is expressed in human umbilical vein endothelium, but is not involved in the inhibition of adenosine transport induced by hyperglycaemia. Placenta 26, 641-653 (2005).
98. Munoz, G. et al. Insulin restores glucose inhibition of adenosine transport by increasing the expression and activity of the equilibrative nucleoside transporter 2 in human umbilical vein endothelium. J. Cell Physiol. 209, 826-835 (2006).
99. Farias, M. et al. Nitric oxide reduces adenosine transporter ENT1 gene (SLC29A1) promoter activity in human fetal endothelium from gestational diabetes. J. Cell Physiol. 208, 451-460 (2006).
100. Farias, M. et al. Nitric oxide reduces SLC29A1 promoter activity and adenosine transport involving transcription factor complex hCHOP-C/EBPα in human umbilical vein endothelial cells from gestational diabetes. Cardiovasc. Res. 86, 45-54 (2010).
101. Westermeier, F. et al. Equilibrative nucleoside transporters in fetal endothelial dysfunction in diabetes mellitus and hyperglycaemia. Curr. Vasc. Pharmacol. 7, 435-449 (2009).
102. 2B adenosine receptor is associated with hyperglycemia in women with gestational diabetes mellitus. Diabetes Metab. Res. Rev. 30, 42-53 (2014).
103. Cusick, M. et al. Associations of mortality and diabetes complications in patients with type 1 and type 2 diabetes: early treatment diabetic retinopathy study report no. 27. Diabetes Care 28, 617-625 (2005).
104. Donnelly, R., Emslie-Smith, A. M., Gardner, I. D. & Morris, A. D. ABC of arterial and venous disease: vascular complications of diabetes. BMJ 320, 1062-1066 (2000).
105. Vinik, A. I., Maser, R. E., Mitchell, B. D. & Freeman, R. Diabetic autonomic neuropathy. Diabetes Care 26, 1553-1579 (2003).
106. Beckman, J. A., Creager, M. A. & Libby, P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287, 2570-2581 (2002).
107. Creager, M. A., Luscher, T. F., Cosentino, F. & Beckman, J. A. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Circulation 108, 1527-1532 (2003).
108. Falcao-Pires, I. & Leite-Moreira, A. F. Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment. Heart Fail. Rev. 17, 325-344 (2012).
109. Auchampach, J. A. & Bolli, R. Adenosine receptor subtypes in the heart: therapeutic opportunities and challenges. Am. J. Physiol. 276, H1113-H1116 (1999).
110. Grden, M., Podgorska, M., Kocbuch, K., Szutowicz, A. & Pawelczyk, T. Expression of adenosine receptors in cardiac fibroblasts as a function of insulin and glucose level. Arch. Biochem. Biophys. 455, 10-17 (2006).
111. 2B receptors in cultured human and porcine coronary artery endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 279, H650-H656 (2000).
112. 3-subtype adenosine receptor is highly expressed in rat vascular smooth muscle cells: its role in attenuating adenosine-induced increase in cAMP. Microvasc. Res. 54, 243-252 (1997).
113. Grden, M., Podgorska, M., Szutowicz, A. & Pawelczyk, T. Altered expression of adenosine receptors in heart of diabetic rat. J. Physiol. Pharmacol. 56, 587-597 (2005).
114. Camelliti, P., Borg, T. K. & Kohl, P. Structural and functional characterisation of cardiac fibroblasts. Cardiovasc. Res. 65, 40-51 (2005).
115. MacKenna, D., Summerour, S. R. & Villarreal, F. J. Role of mechanical factors in modulating cardiac fibroblast function and extracellular matrix synthesis. Cardiovasc. Res. 46, 257-263 (2000).
116. Bell, D. S. Heart failure: the frequent, forgotten, and often fatal complication of diabetes. Diabetes Care 26, 2433-2441 (2003).
117. 2B adenosine receptor, attenuates cardiac remodeling after acute myocardial infarction in the mouse. J. Pharmacol. Exp. Ther. 343, 587-595 (2012).
118. 2B adenosine receptor reduces left ventricular dysfunction and ventricular arrhythmias 1 week after myocardial infarction in the rat model. Heart Rhythm 11, 101-109 (2014).
119. Horvath, B., Mukhopadhyay, P., Hasko, G. & Pacher, P. The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications. Am. J. Pathol. 180, 432-442 (2012).
120. 2b receptor. Hypertension 27, 786-793 (1996).
121. 2B receptors. Hypertension 31, 516-521 (1998).
122. 2B receptors mediate the induction of early genes and inhibition of arterial smooth muscle cell proliferation via Epac. Cardiovasc. Res. 90, 148-156 (2011).
123. Pares-Herbute, N. et al. Adenosine inhibitory effect on enhanced growth of aortic smooth muscle cells from streptozotocin-induced diabetic rats. Br. J. Pharmacol. 118, 783-789 (1996).
124. 2b adenosine receptor regulates hyperlipidemia and atherosclerosis. Circulation 125, 354-363 (2012).
125. Ni, W. J., Tang, L. Q. & Wei, W. Research progress on signaling pathway in diabetic nephropathy. Diabetes Metab. Res. Rev. http://dx.doi.org/10.1002/dmrr.2568.
126. Schena, F. P. & Gesualdo, L. Pathogenetic mechanisms of diabetic nephropathy. J. Am. Soc. Nephrol. 16 (Suppl. 1), S30-S33 (2005).
127. Elsherbiny, N. M. & Al-Gayyar, M. M. Adenosine receptors: new therapeutic targets for inflammation in diabetic nephropathy. Inflamm. Allergy Drug Targets. 12, 153-161 (2013).
128. Vallon, V. & Osswald, H. Adenosine receptors and the kidney. Handb. Exp. Pharmacol. 193, 443-470 (2009).
129. Pawelczyk, T., Grden, M., Rzepko, R., Sakowicz, M. & Szutowicz, A. Region-specific alterations of adenosine receptors expression level in kidney of diabetic rat. Am. J. Pathol. 167, 315-325 (2005).
130. Pawelczyk, T., Podgorska, M. & Sakowicz, M. The effect of insulin on expression level of nucleoside transporters in diabetic rats. Mol. Pharmacol. 63, 81-88 (2003).
131. Persson, P., Hansell, P. & Palm, F. Tubular reabsorption and diabetes-induced glomerular hyperfiltration. Acta Physiol. (Oxf.) 200, 3-10 (2010).
132. 1 adenosine receptors augments diabetic hyperfiltration and glomerular injury. J. Am. Soc. Nephrol. 19, 722-730 (2008).
133. 1-receptor deficient mice lacking the tubuloglomerular feedback mechanism. Acta Physiol. (Oxf.) 190, 253-259 (2007).
134. Tesch, G. H. Macrophages and diabetic nephropathy. Semin. Nephrol. 30, 290-301 (2010).
135. 2A receptor activation attenuates inflammation and injury in diabetic nephropathy. Am. J. Physiol. Renal Physiol. 290, F828-F837 (2006).
136. Roa, H. et al. Adenosine mediates transforming growth factor-(31 release in kidney glomerul of diabetic rats. FEBS Lett. 583, 3192-3198 (2009).
137. 2B receptor-mediated VEGF induction promotes diabetic glomerulopathy. Lab. Invest. 93, 135-144 (2013).
138. Tak, E. et al. CD73-dependent generation of adenosine and endothelial Adora2b signaling attenuate diabetic nephropathy. J. Am. Soc. Nephrol. 25, 547-563 (2014).
139. Lois, N., McCarter, R. V., O'Neill, C, Medina, R. J. & Stitt, A. W. Endothelial progenitor cells n diabetic retinopathy. Front. Endocrinol. (Lausanne) 5, 44 (2014).
140. Antonetti, D. A., Klein, R. & Gardner, T. W. Diabetic retinopathy. N. Engl. J. Med. 366, 1227-1239 (2012).
141. Vindeirinho, J., Costa, G. N., Correia, M. B., Cavadas, C. & Santos, P. F. Effect of diabetes/hyperglycemia on the rat retinal adenosinergic system. PLoS ONE 8, e67499 (2013).
142. Elsherbiny, N. M. et al. Potential roles of adenosine deaminase-2 in diabetic retinopathy. Biochem. Biophys. Res. Commun. 436, 355-361 (2013).
143. 2AAR) as a therapeutic target n diabetic retinopathy. Am. J. Pathol. 178, 2136-2145 (2011).
144. Elsherbiny, N. M. et al. ABT-702, an adenosine kinase inhibitor, attenuates inflammation in diabetic retinopathy. Life Sci. 93, 78-88 (2013).
145. Charles, B. A. et al. Variants of the adenosine A 2A receptor gene are protective against proliferative diabetic retinopathy in patients with type 1 diabetes. Ophthalmic Res. 46, 1-8 (2011).
146. Charnogursky, G., Lee, H. & Lopez, N. Diabetic neuropathy. Handb. Clin. Neurol. 120, 773-785 (2014).
147. Said, G. Diabetic neuropathy-a review. Nat. Clin. Pract. Neurol. 3, 331-340 (2007).
148. Sawynok, J. & Liu, X. J. Adenosine in the spinal cord and periphery: release and regulation of pain. Prog. Neurobiol. 69, 313-340 (2003).
149. rd, Jarvis, M. F & Kowaluk, E. A. An adenosine kinase inhibitor attenuates tactile allodynia in a rat model of diabetic neuropathic pain. Eur. J. Pharmacol. 364, 141-146 (1999).
150. Saini, A. K., Arun, K. H., Kaul, C. L. & Sharma, S. S. Acute hyperglycemia attenuates nerve conduction velocity and nerve blood flow in male Sprague-Dawley rats: reversal by adenosine. Pharmacol. Res. 50, 593-599 (2004).
151. Amadio, S., Apolloni, S., D'Ambrosi, N. & Volonte, C. Purinergic signalling at the plasma membrane: a multipurpose and multidirectional mode to deal with amyotrophic lateral sclerosis and multiple sclerosis. J. Neurochem. 116, 796-805 (2011).
152. POS regulatory T cells and aberrant control of T-helper type 17 cells in autoimmune hepatitis. Hepatology 59, 1007-1015 (2014).
153. de Galan, B. E. et al. Theophylline improves hypoglycemia unawareness in type 1 diabetes. Diabetes 51, 790-796 (2002).
154. Arias, A. M. et al. Aminophylline stimulates insulin secretion in patients with type 2 diabetes mellitus. Metabolism 50, 1030-1035 (2001).
155. Hopper, A. H., Tindall, H. & Davies, J. A. Administration of aspirin-dipyridamole reduces proteinuria in diabetic nephropathy. Nephrol. Dial. Transplant. 4, 140-143 (1989).
156. Aizawa, T. et al. Dipyridamole reduces urinary albumin excretion in diabetic patients with normo-or microalbuminuria. Clin. Nephrol. 33, 130-135 (1990).
157. Bonello, L. et al. Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome. J. Am. Coll. Cardiol. 63, 872-877 (2014).
158. Laine, M. et al. Ticagrelor versus prasugrel in diabetic patients with an acute coronary syndrome. A pharmacodynamic randomised study. Thromb. Haemost. 111, 273-278 (2014).
159. Natella, F. & Scaccini, C. Role of coffee in modulation of diabetes risk. Nutr. Rev. 70, 207-217 (2012).
160. Jacobson, K. A. & Gao, Z. G. Adenosine receptors as therapeutic targets. Nat. Rev. Drug Discov. 5, 247-264 (2006).
161. Jiang, X., Zhang, D. & Jiang, W. Coffee and caffeine intake and incidence of type 2 diabetes mellitus: a meta-analysis of prospective studies. Eur. J. Nutr. 53, 25-38 (2014).
162. Bhupathiraju, S. N. et al. Changes in coffee intake and subsequent risk of type 2 diabetes: three large cohorts of US men and women. Diabetologia 57, 1346-1354 (2014).
163. van Dam, R. M. & Hu, F. B. Coffee consumption and risk of type 2 diabetes: a systematic review. JAMA 294, 97-104 (2005).
164. Ding, M., Bhupathiraju, S. N., Chen, M., van Dam, R. M. & Hu, F. B. Caffeinated and decaffeinated coffee consumption and risk of type 2 diabetes: a systematic review and a dose-response meta-analysis. Diabetes Care 37, 569-586 (2014).
165. Krebs, J. D., Parry-Strong, A., Weatherall, M., Carroll, R. W. & Downie, M. A cross-over study of the acute effects of espresso coffee on glucose tolerance and insulin sensitivity in people with type 2 diabetes mellitus. Metabolism 61, 1231-1237 (2012).
166. Salazar-Martinez, E. et al. Coffee consumption and risk for type 2 diabetes mellitus. Ann. Intern. Med. 140, 1-8 (2004).
167. y mice. J. Agric. Food Chem. 58, 5597-5603 (2010).
168. y mice. J. Oleo. Sci. 61, 515-523 (2012).